227 related articles for article (PubMed ID: 18458136)
61. [Study on in vitro susceptibility of Candida spp. isolated from blood culture].
Grandesso S; Sapino B; Mazzuccato S; Solinas M; Bedin M; D'Angelo M; Gion M
Infez Med; 2012 Mar; 20(1):25-30. PubMed ID: 22475657
[TBL] [Abstract][Full Text] [Related]
62. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Barton R; Bijie H; Bille J; Chang SC; da Luz Martins M; Duse A; Dzierzanowska D; Ellis D; Finquelievich J; Gould I; Gur D; Hoosen A; Lee K; Mallatova N; Mallie M; Peng NG; Petrikos G; Santiago A; Trupl J; VanDen Abeele AM; Wadula J; Zaidi M;
Diagn Microbiol Infect Dis; 2010 Jun; 67(2):162-71. PubMed ID: 20338711
[TBL] [Abstract][Full Text] [Related]
63. In vitro synergistic antifungal activities of caspofungin in combination with fluconazole or voriconazole against Candida species determined by the Etest method.
Yang Q; Liu Z; Wang Y; Xie J; Zhang K; Dong Y; Wang YF
Int J Infect Dis; 2022 Sep; 122():982-990. PubMed ID: 35907476
[TBL] [Abstract][Full Text] [Related]
64. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
Drago M; Scaltrito MM; Morace G;
Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
[TBL] [Abstract][Full Text] [Related]
65. In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms.
Ko KS; Lee JY; Song JH; Peck KR
J Korean Med Sci; 2010 Dec; 25(12):1722-6. PubMed ID: 21165285
[TBL] [Abstract][Full Text] [Related]
66. APX001A
Arendrup MC; Chowdhary A; Astvad KMT; Jørgensen KM
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104264
[TBL] [Abstract][Full Text] [Related]
67. In vitro activity of voriconazole against Candida species isolated in Taiwan.
Yang YL; Cheng HH; Lo HJ
Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
[TBL] [Abstract][Full Text] [Related]
68. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
69. Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates.
Arendrup MC; Park S; Brown S; Pfaller M; Perlin DS
Antimicrob Agents Chemother; 2011 May; 55(5):1891-5. PubMed ID: 21357293
[TBL] [Abstract][Full Text] [Related]
70. In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
Bordallo-Cardona MÁ; Escribano P; de la Pedrosa EG; Marcos-Zambrano LJ; Cantón R; Bouza E; Guinea J
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872063
[TBL] [Abstract][Full Text] [Related]
71. In vitro activities of nine antifungal drugs against 81 Phialophora and Cyphellophora isolates.
Feng P; Najafzadeh MJ; Sun J; Ahmed S; Xi L; de Hoog GS; Lai W; Lu C; Klaassen CH; Meis JF
Antimicrob Agents Chemother; 2012 Nov; 56(11):6044-7. PubMed ID: 22948876
[TBL] [Abstract][Full Text] [Related]
72. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
73. Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes.
Baltch AL; Bopp LH; Smith RP; Ritz WJ; Michelsen PB
J Antimicrob Chemother; 2008 Dec; 62(6):1285-90. PubMed ID: 18772160
[TBL] [Abstract][Full Text] [Related]
74. Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent Candida spp.
Cretella D; Barber KE; King ST; Stover KR
J Med Microbiol; 2016 Dec; 65(12):1445-1451. PubMed ID: 27902377
[TBL] [Abstract][Full Text] [Related]
75. Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp.
Peterson JF; Pfaller MA; Diekema DJ; Rinaldi MG; Riebe KM; Ledeboer NA
J Clin Microbiol; 2011 May; 49(5):1765-71. PubMed ID: 21430096
[TBL] [Abstract][Full Text] [Related]
76. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
Roling EE; Klepser ME; Wasson A; Lewis RE; Ernst EJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 May; 43(1):13-7. PubMed ID: 12052624
[TBL] [Abstract][Full Text] [Related]
77. In vitro Synergistic Activity of Caspofungin Plus Polymyxin B Against Fluconazole-Resistant Candida glabrata.
Adams EK; Ashcraft DS; Pankey GA
Am J Med Sci; 2016 Mar; 351(3):265-70. PubMed ID: 26992255
[TBL] [Abstract][Full Text] [Related]
78. Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland.
Seneviratne CJ; Wong SS; Yuen KY; Meurman JH; Pärnänen P; Vaara M; Samaranayake LP
Mycopathologia; 2011 Nov; 172(5):389-95. PubMed ID: 21744043
[TBL] [Abstract][Full Text] [Related]
79. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.
Panackal AA; Gribskov JL; Staab JF; Kirby KA; Rinaldi M; Marr KA
J Clin Microbiol; 2006 May; 44(5):1740-3. PubMed ID: 16672401
[TBL] [Abstract][Full Text] [Related]
80. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.
Pfaller MA; Diekema DJ; Boyken L; Messer SA; Tendolkar S; Hollis RJ
J Clin Microbiol; 2003 May; 41(5):1875-80. PubMed ID: 12734220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
